Neuroone Medical Technologies (NMTC) Return on Equity (2016 - 2025)
Neuroone Medical Technologies' Return on Equity history spans 12 years, with the latest figure at 1.01% for Q4 2025.
- For Q4 2025, Return on Equity rose 281.0% year-over-year to 1.01%; the TTM value through Dec 2025 reached 1.01%, up 281.0%, while the annual FY2025 figure was 0.91%, 257.0% up from the prior year.
- Return on Equity reached 1.01% in Q4 2025 per NMTC's latest filing, down from 0.47% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.47% in Q3 2025 to a low of 6.43% in Q3 2024.
- Average Return on Equity over 5 years is 1.94%, with a median of 1.22% recorded in 2021.
- Peak YoY movement for Return on Equity: crashed -409bps in 2024, then soared 595bps in 2025.
- A 5-year view of Return on Equity shows it stood at 0.96% in 2021, then decreased by -5bps to 1.0% in 2022, then tumbled by -152bps to 2.53% in 2023, then crashed by -51bps to 3.83% in 2024, then surged by 74bps to 1.01% in 2025.
- Per Business Quant, the three most recent readings for NMTC's Return on Equity are 1.01% (Q4 2025), 0.47% (Q3 2025), and 1.15% (Q2 2025).